Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 ...

Jeetah received India's first indigenously developed CAR-T therapy, designed and manufactured by ImmunoACT, a company incubated at IIT Bombay in collaboration with Tata Memorial Centre. The infusion ...

Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...

Chimeric antigen receptor T-cell therapy (CAR T) has revolutionized oncology treatment over the last decade, offering targeted therapy options for several difficult cancers, espec ...

By using CRISPR/Cas9 to engineer cells from healthy donors, AVC-203 is designed to circumvent graft-versus-host disease and host-mediated rejection.

BostonGene, a developer of the leading AI foundation model for tumor and immune biology, today announced that 13 abstracts have been selected for presentation at the American Association for Cancer ...

Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...

Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD ...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 ...

Detailed price information for Adc Therapeutics Sa (ADCT-N) from The Globe and Mail including charting and trades.

Researchers assessed the safety and efficacy of the novel PolaR-ICE regimen among patients with relapsed or refractory DLBCL in the second-line setting.

A new study published in The Journal of Immunology by researchers at the Josep Carreras Leukaemia Research Institute (IJC) ...